America Movil SAB de CV ADR (AMX)vsJohnson & Johnson (JNJ)
AMX
America Movil SAB de CV ADR
$24.76
+4.52%
COMMUNICATION SERVICES · Cap: $70.61B
JNJ
Johnson & Johnson
$239.93
+1.98%
HEALTHCARE · Cap: $567.22B
Smart Verdict
WallStSmart Research — data-driven comparison
America Movil SAB de CV ADR generates 902% more annual revenue ($943.64B vs $94.19B). JNJ leads profitability with a 28.5% profit margin vs 8.8%. AMX appears more attractively valued with a PEG of 1.17. JNJ earns a higher WallStSmart Score of 71/100 (B).
AMX
Strong Buy69
out of 100
Grade: B-
JNJ
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.3%
Fair Value
$72.07
Current Price
$24.76
$47.31 discount
Margin of Safety
+54.5%
Fair Value
$516.67
Current Price
$239.93
$276.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Generating 42.7B in free cash flow
Large-cap with strong market position
Every $100 of equity generates 21 in profit
Attractively priced relative to earnings
Strong operational efficiency at 20.1%
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Keeps 28 of every $100 in revenue as profit
Strong operational efficiency at 24.0%
Earnings expanding 48.6% YoY
Generating 5.5B in free cash flow
Areas to Watch
3.4% revenue growth
4.0% earnings growth
Trading at 72.8x book value
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMX
The strongest argument for AMX centers on Free Cash Flow, Market Cap, Return on Equity. PEG of 1.17 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 28.5% and operating margin at 24.0%.
Bear Case : AMX
The primary concerns for AMX are Revenue Growth, EPS Growth, Price/Book. Debt-to-equity of 2.53 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are PEG Ratio.
Key Dynamics to Monitor
AMX profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
AMX carries more volatility with a beta of 0.37 — expect wider price swings.
JNJ is growing revenue faster at 9.1% — sustainability is the question.
AMX generates stronger free cash flow (42.7B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (71/100 vs 69/100), backed by strong 28.5% margins. AMX offers better value entry with a 67.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
America Movil SAB de CV ADR
COMMUNICATION SERVICES · TELECOM SERVICES · USA
Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other TELECOM SERVICES Stocks
Want to dig deeper into these stocks?